FDAsafety guidance66% confidence
Drug Trials Snapshots: YARTEMLEA
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for YARTEMLEA; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
YARTEMLEA is a prescription drug that is MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Supporting Context
- Therapeutic area
- Hematology · Thrombotic Microangiopathy
- Sub-indication
- General
Related signal: FDA Drug Trials Snapshot: YARTEMLEA Approved for TA-TMA